Year: 2019

FORT WORTH, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) — Pure Acquisition Corp. (“Pure”) (NASDAQ: PACQ, PACQU, PACQW), a special purpose acquisition company focused on oil and gas exploration and production, today announced that it has named Michael L. Hollis as President.  Mr. Hollis is also expected to be named President of HighPeak Energy, Inc. (“HighPeak”) upon the consummation of Pure’s business combination, which is expected to close in the first quarter of 2020.  On November 27, 2019, Pure announced that it had entered into a business combination agreement with HighPeak and certain affiliates of HighPeak Energy Partners, LP and a contribution agreement with Grenadier Energy Partners II, LLC.  HighPeak filed a Form S-4 Registration Statement with the Securities and Exchange Commission on December 2, 2019.Mr. Hollis joins Pure most...

DAYTONA BEACH, Fla., Dec. 09, 2019 (GLOBE NEWSWIRE) — J. Scott Penny, Chief Acquisitions Officer of Brown & Brown, Inc. (NYSE:BRO), and Mark Woodall and Tom Willie, the principals of Special Risk Insurance Managers, Ltd. (“Special Risk”), today announced that Brown & Brown Programs (CA), Inc. has entered into an agreement to acquire the assets of Special Risk.  The transaction is expected to close effective January 1, 2020, subject to certain closing conditions.Founded in 1991, Special Risk has grown to a preeminent player in the MGA industry in Canada, recognized as MGA of the Year in 2018.  The acquisition of Special Risk is a strategic step forward for Brown & Brown in establishing a presence in the Canadian insurance brokerage market.  Special Risk will operate as a part of Brown & Brown National Programs,...

BROOKFIELD, NEWS, Dec. 09, 2019 (GLOBE NEWSWIRE) — Genworth Financial, Inc. (NYSE: GNW) and Brookfield Business Partners (NYSE: BBU) (TSX: BBU.UN) today announced that Brookfield Business Partners together with its institutional partners has received approval under the Insurance Companies Act (Canada) to purchase Genworth’s majority interest in Genworth MI Canada Inc. (Genworth Canada). All regulatory approvals required for the completion of this transaction have now been obtained.The parties expect to complete the Genworth Canada transaction on December 12, 2019.About Brookfield Business PartnersBrookfield Business Partners is a business services and industrials company focused on owning and operating high-quality businesses that benefit from barriers to entry and/or low production costs.Brookfield Business Partners is the flagship...

EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 89,000 shares of the company’s common stock, at a per share exercise price of $6.48, the closing trading price on December 6, and restricted stock units to acquire 44,500 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company’s board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.About Adamas Pharmaceuticals,...

MOUNTAIN VIEW, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) — Livongo Health, Inc. (Nasdaq: LVGO) today announced plans for the commencement of an underwritten public offering of 2,777,327 shares of common stock by certain selling stockholders. Such selling stockholders also intend to grant the underwriters a 30-day option to purchase up to an additional 416,598 shares of common stock at the public offering price, less underwriting discounts and commissions. Livongo will not receive any of the proceeds from the proposed sale of the shares of its common stock being offered by the selling stockholders, and will bear the costs associated with the cost of such transaction, other than underwriting discounts and commissions.  The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when...

Sanofi CEO unveils new strategy to drive innovation and growthPrioritize key growth drivers – Dupixent® (dupilumab) and vaccinesAccelerate R&D focus on six potentially transformative medicinesImprove operating efficiencies to fund growth and expand business operating income margin1Align to support new strategy with three core businesses and a standalone consumer healthcare unitPARIS – DECEMBER 9, 2019 – At Sanofi’s Capital Markets Day tomorrow with the financial community, the company will provide details of a new strategic framework with four key priorities to drive innovation and growth. Sanofi will also discuss the alignment of the organization to support this new strategy.Sanofi Chief Executive Officer Paul Hudson and Executive Committee members will provide a detailed overview of the company’s strategy based on four main priorities...

Le Directeur Général de Sanofi dévoile sa stratégie pour dynamiser l’innovation et la croissance de l’entreprisePrincipaux leviers de croissance : Dupixent® (dupilumab) et les vaccinsIntensifier les efforts de R&D sur six médicaments ayant le potentiel de transformer la prise en charge des patientsAméliorer l’efficacité opérationnelle pour financer la croissance et renforcer la marge opérationnelle des activités1Aligner l’organisation pour soutenir la nouvelle stratégie : trois entités principales et une entité Santé Grand Public autonomePARIS – LE 9 DÉCEMBRE 2019 – Sanofi réunit demain des représentants de la communauté financière à l’occasion de son Capital Markets Day afin de présenter la nouvelle stratégie avec quatre grandes priorités qui permettront de dynamiser la croissance et le potentiel d’innovation de l’entreprise. Sanofi...